OMEROS CORP (OMER): debt financing — Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%

OMEROS CORP

2025-Q1 EPS reported -$0.58

Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.
Cash and short-term investments $52.4M at Mar 31, 2025, down $37.7M from Dec 31, 2024.
Exchanged $70.8M of 5.25% 2026 notes for new 9.50% 2029 notes; additionally $10M notes converting to equity.
Outstanding 2026 notes reduced to ~$17.1M; avoids $20M term loan prepayment plus $1M premium due Nov 2025.
FDA accepted BLA for narsoplimab in TA-TMA; PDUFA date Sep 25, 2025. Phase 3 PNH program paused to conserve cash.

item 1.01 item 2.02 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

OMEROS CORP incurred convertible notes of $70.8 million aggregate principal amount with Computershare Trust Company, National Association, as trustee at 9.50% per annum maturing June 15, 2029.

Instrument: convertible notes
Principal: $70.8 million aggregate principal amount
Counterparty: Computershare Trust Company, National Association, as trustee
Rate: 9.50% per annum
Maturity: June 15, 2029
Event: incurrence

Exact text from the filing

On May 14, 2025, Omeros Corporation (the “Company”) completed the private exchange (the “Exchange”) of approximately $70.8 million aggregate principal amount of its outstanding Convertible Senior Notes due 2026 (the “2026 Notes”) on a one-for-one basis for newly issued Convertible Senior Notes due 2029 (the “New Notes”).

View on SEC.gov

Browse all debt financings →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001437749-25-017211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.